Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.

CompletedOBSERVATIONAL
Enrollment

296

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Sepsis
Interventions
DEVICE

Blood sampling

Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).

Trial Locations (14)

1011

Centre Hospitalier Universitaire Vaudois, Service of Adult Intensive Care, Lausanne

1205

Hopitaux Universitaires de Genève, Service des soins intensifs, Département APSI, Geneva

3010

Bern University Hospital, Universitätsklinik für Intensivmedizin, Bern

6156

Ospedale Santa Maria della Misericordia, Terapia Intensiva, Perugia

10154

Ospedale San Giovanni Bosco, Servizio Anestesia e Rianimazione, Torino

37044

Hôpital Bretonneau, CHU de Tours, Médecine Intensive - Réanimation, Tours

47921

Ospedale Infermi, Dept Anesthesia and ICU, Rimini

48121

Ospedale Santa Maria delle Croci, Terapia Intensiva, Ravenna

69495

CH Lyon-Sud, Services de soins critiques, Pierre-Bénite

72037

CH Le Mans, Service de Réanimation Médico Chirurgicale & USC, Le Mans

87042

CHU Limoges, Réanimation Polyvalente, Limoges

GU2 7XX

Royal Surrey County Hospital, Intensive Care Medicine, Guildford

NW1 2BU

University College London Hospitals, Anaesthetics Department, London

SE1 7EH

Guy's & St Thomas' Hospital, Department of Critical Care, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abionic SA

INDUSTRY

NCT03474809 - Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope. | Biotech Hunter | Biotech Hunter